Department of Forensic Medicine and Toxicology, Medical School, University of Athens, Athens, Greece.
Clin Chem Lab Med. 2010 Jul;48(7):1035-41. doi: 10.1515/CCLM.2010.211.
Neutrophil gelatinase-associated lipocalin (NGAL) is well established as an early and specific biomarker of kidney disease. Recent evidence further suggests that NGAL may play a crucial role in vascular remodeling and plaque instability during the development of atherosclerosis.
Plasma NGAL concentrations measured using a solid-phase enzyme-linked immunosorbent assay (ELISA) were correlated with medical history, risk factors and medication intake in 141 patients with advanced carotid atherosclerotic lesions who underwent carotid endarterectomy for vascular repair.
Plasma NGAL concentrations were associated with patient age (R(s)=0.2055, p=0.0144), plasma homocysteine (R(s)=0.4274, p<0.00001) and serum creatinine (R(s)=0.4640, p<0.00001) concentrations and estimated glomerular filtration rate (eGFR) (R(s)=-0.4911, p<0.00001). Hypertensive patients, as well as those receiving therapy with angiotensin converting enzyme (ACE) inhibitors, presented with significantly enhanced plasma NGAL concentrations when compared to normotensive (p=0.0341) patients and those not treated (p=0.0004). Enhanced NGAL concentrations did not meet statistical significance for patients with advanced stenosis grade (p=0.0971) or a history of peripheral artery disease (p=0.0827). Multiple regression analysis identified homocysteine, creatinine, eGFR and treatment with ACE inhibitors (p=0.0019, <0.00001, 0.0005 and 0.0219, respectively) as independent predictors of NGAL concentration.
Plasma NGAL concentrations were associated with patient age, hypertension, eGFR, creatinine and homocysteine concentrations and therapy with ACE inhibitors. The role of NGAL in the development of atherosclerosis needs to be further explored taking into consideration the uncontrolled effect of renal disease in atherosclerotic patients with multiple risk factors.
中性粒细胞明胶酶相关脂质运载蛋白（NGAL）是一种公认的肾脏疾病早期特异性生物标志物。最近的证据进一步表明，NGAL 在动脉粥样硬化发展过程中的血管重塑和斑块不稳定性中可能发挥关键作用。
采用固相酶联免疫吸附测定法（ELISA）检测 141 例颈动脉粥样硬化病变患者的血浆 NGAL 浓度，这些患者因血管修复而行颈动脉内膜切除术。将其与病史、危险因素和药物摄入相关联。
血浆 NGAL 浓度与患者年龄（R(s)=0.2055，p=0.0144）、血浆同型半胱氨酸（R(s)=0.4274，p<0.00001）和血清肌酐（R(s)=0.4640，p<0.00001）浓度及估计肾小球滤过率（eGFR）（R(s)=-0.4911，p<0.00001）相关。与血压正常的患者（p=0.0341）和未接受治疗的患者（p=0.0004）相比，高血压患者和接受血管紧张素转换酶（ACE）抑制剂治疗的患者血浆 NGAL 浓度明显升高。对于狭窄程度较高的患者（p=0.0971）或有外周动脉疾病病史的患者（p=0.0827），升高的 NGAL 浓度无统计学意义。多元回归分析显示，同型半胱氨酸、肌酐、eGFR 和 ACE 抑制剂治疗（p=0.0019、<0.00001、0.0005 和 0.0219）是 NGAL 浓度的独立预测因子。
血浆 NGAL 浓度与患者年龄、高血压、eGFR、肌酐和同型半胱氨酸浓度以及 ACE 抑制剂治疗相关。考虑到伴有多种危险因素的动脉粥样硬化患者的肾脏疾病存在不可控作用，需要进一步探讨 NGAL 在动脉粥样硬化发展中的作用。
Zotero 插件